Transgene, Roche Enter Potential $293M Alliance On HPV Vaccine April 12, 2007 By Jim Shrine Transgene SA entered its first product-development deal, a collaboration worth up to €218 million (US$293) on its late-stage therapeutic vaccine against human papillomavirus-related diseases. (BioWorld Today)Read More
RSS